Molecular Imaging Insider

Dear Molecular Imaging Insider,

Hybrid imaging was a popular theme at RSNA 2017, and among the highlights were new findings from Germany about the efficacy of PET/MRI for women's imaging. The results of a study that compared the hybrid modality in the prone and supine position with breast MRI could very well surprise some readers. Get the details by clicking here.

Also at RSNA 2017, researchers from Spain shed light on how they use PET/CT and MRI to predict which lesions could progress to malignant neurofibromas. Their study details which key indicators can help radiologists differentiate between benign and malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. They included the size of the lesion, its growth rate, and possible expansion into adjacent areas.

Meanwhile, low-cost, 3D printing technology is contributing to the creation of kidney phantoms that provide shape-specific details designed to improve the quantification of SPECT/CT scans. Researchers from Würzburg, Germany, have published an article in the Journal of Nuclear Medicine about the viability of a two-compartment model using 3D printing to identify the optimal SPECT/CT postreconstruction method for determining the activity of a lutetium-177 (Lu-177) radiopharmaceutical in the kidney.

Elsewhere, the European Medicines Agency is relocating to a new home. It took three rounds of voting before the European Union chose Amsterdam to host approximately 900 staff members. Find out when the move from London to the Dutch city will happen.

Austrian and U.S. researchers have increased the detection of disease recurrence after radical prostatectomy by using PET imaging with a novel gallium-68 prostate-specific membrane antigen conjugated ligand. The findings are quite encouraging for the detection of recurrent prostate cancer at relatively low prostate-specific antigen (PSA) levels.

I would like to wish all our readers a joyous holiday season and a very healthy and prosperous 2018. We look forward to your visits to the Molecular Imaging Community in the new year.

Page 1 of 113
Next Page